No Data
No Data
Mesoblast Expands Insurance Coverage for Ryoncil to 104 Million Lives in US
Mesoblast Target Price Cut 13% to A$3.40/Share by Bell Potter>MSB.AU
Top Broker Says Mesoblast Shares Can Rocket 100%
Express News | Mesoblast Ltd - Mesoblast Cell Therapy Products Not Subject to U.S. Tariffs
Mesoblast Files Request for Type B Meeting With FDA to Discuss Accelerated Approval Pathway for Revascor in Ischemic Heart Failure
Mesoblast (ASX:MSB) Announces Ryoncil Availability But Sees 15% Price Drop Over Past Week
PAUL BIN ANTHONY : good luck